A French prospective observational study of the treatment of chronic hepatitis C in drug abusers

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 10, 2008, Pages 850-857

  Chossegros, P ^a   Melin P ^b   Hezode C ^c   Bourliere M ^d   Pol, S ^e   Fhima, A ^f   Filoche, B ^g   Trepo C ^h   Couzigou, P ⁱ   Ouzan, D ^j   Gagnon, A ^f  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Hôpital Saint Dizier   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL SAINT JOSEPH   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f GP Lyon ^*  (France)

^g Centre Hospitalier Saint Philibert GHICL   (France)

^h HÔTEL DIEU   (France)

ⁱ HAUT LÉVÊQUE HOSPITAL   (France)

^j INSTITUT ARNAULT TZANCK   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BUPRENORPHINE; METHADONE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG MEGADOSE; FEMALE; FOLLOW UP; FRANCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; FEMALE; FRANCE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 54049144372     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.07.004     Document Type: Article

References (34)

1. Drogues et dépendances : indicateurs et tendances. Édition 2002 p28. www.drogues.gouv.fr Professionnels/ressources documentaries.
2. Cadet-Taïrou A., Costes J.M., Lopez D., Martineau H., Obradovic I., Palle C., et al. Drogues et dépendances, données essentielles: parution de la cinquième édition de l'état des lieux sur le phénomène des drogues en France, produit par l'OFDT. Tendances 42 (2005) 17-22
3. Drugs and dependence. Indicators and trends in 2002. Tendances Letter 2002; 19:1-6.
4. Cadet-Tairou A., Costes J.M., Bello P.Y., and Palle C. Les traitements de substitution en France : résultats récents 2004. Tendances 37 (2004) 8
5. Desenclos J.C. Épidémiologie de l'hépatite C. Rev Prat 50 (2000) 1066-1070
6. Lucidarme D., Bruandet A., Ilef D., Harbonnier J., Jacob C., Decoster A., et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 132 (2004) 699-708
7. Dubois F., Desenclos J.-C., Mariotte N., Goudeau A., and the Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 25 (1997) 1490-1496
8. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90 (2000) 1562-1569
9. Deuffic-Burban S., Wong J.B., Valleron A.J., Costagliola D., Delfraissy J.F., and Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 40 (2004) 319-326
10. McCarthy J.J., and Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 20 (2001) 19-31
11. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med 345 (2001) 211-215
12. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA 285 (2001) 1003-1005
13. Taylor L.E., Schwartzapfel B., Allen S., Jacobs G., and Mitty J. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence. Clin Infect Dis 36 (2003) 1501-1502
14. Schaefer M., Heinz A., and Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 99 (2004) 1167-1175
15. Seeff L.B., and Hoofnagle J.H. Appendix: The national institutes of health consensus development conference management of hepatitis C 2002. Clin Liver Dis 7 (2003) 261-287
16. Sylvestre D.L., Loftis J.M., Hauser P., Genser S., Cesari H., Borek N., et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 81 (2004) 719-734
17. Jowett S.L., Agarwal K., Smith B.C., Craig W., Hewett M., Bassendine D.R., et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 94 (2001) 153-158
18. Sylvestre D.L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 67 (2002) 117-123
19. Backmund M., Meyer K., Von Zielonka M., and Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34 (2001) 188-193
20. Mauss S., Berger F., Goelz J., Jacob B., and Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40 (2004) 120-124
21. Grando-Lemaire V., Goisset P., Sorge F., Trinchet J.-C., Castera L., Roulot D., et al. Prise en charge de l'infection par le virus de l'hépatite C dans une population de toxicomanes suivis dans un centre spécialisé ambulatoire. Gastroenterol Clin Biol 26 (2002) 1091-1096
22. Dalgard O., Bjoro K., Hellum K., Myrvang B., Skaug K., Gutigard B., et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 8 (2002) 45-49
23. Van Thiel D.H., Anantharaju A., and Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 98 (2003) 2281-2288
24. Cournot M., Glibert A., Castel F., Druart F., Imani K., Lauwers-Cances V., et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 28 (2004) 533-539
25. Neri S., Bruno C.M., Abate G., Ierna D., Mauceri B., Cilio D., et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-α2b. Clin Ther 24 (2002) 1627-1635
26. Fontanges T., Beorchia S., Douvin C., Delassalle P., Combis J.M., Hanslik B., et al. Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Gastroenterol Clin Biol 31 (2007) 566-572
27. Hatem C., Minello A., Martin L., Jooste V., Beurton I., Milan C., et al. Management of hepatitis C patients: a French population-based study. Gastroenterol Clin Biol 28 (2004) 1101-1105
28. Pariente A., Djilloul A., Cadranel J.F., and Association Nationale des Gastroentérologues des Hôpitaux Généraux (ANGH). Traitement de l'hépatite chronique C par interféron alpha et ribavirine. Résultats dans la « vrai vie ». Gastroenterol Clin Biol 27 (2003) 590-595
29. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 (2000) 21-30
30. Capuron L., and Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 340 (1999) 1370
31. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344 (2001) 961-966
32. Van Thiel D.H., Friedlander L., Molloy P.J., Fagiuoli S., Kania R.J., and Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 7 (1995) 165-168
33. Prochaska J.O., and Velicer W.F. The transtheoretical model of health behavior change. Am J Health Promot 12 (1997) 38-48
34. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965